On Monday, BioAtla Inc (NASDAQ: BCAB) opened lower -3.21% from the last session, before settling in for the closing price of $1.56. Price fluctuations for BCAB have ranged from $1.14 to $4.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -56.91% over the last five years. Company’s average yearly earnings per share was noted 40.93% at the time writing. With a float of $39.02 million, this company’s outstanding shares have now reached $48.08 million.
The firm has a total of 65 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.41%, operating margin of -678.7%, and the pretax margin is -643.92%.
BioAtla Inc (BCAB) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BioAtla Inc is 19.30%, while institutional ownership is 32.54%. The most recent insider transaction that took place on Dec 26 ’23, was worth 9,320. In this transaction Director of this company bought 4,000 shares at a rate of $2.33, taking the stock ownership to the 15,125 shares. Before that another transaction happened on Dec 20 ’23, when Company’s Chief Executive Officer bought 50,000 for $2.14, making the entire transaction worth $106,910. This insider now owns 1,439,283 shares in total.
BioAtla Inc (BCAB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 40.93% per share during the next fiscal year.
BioAtla Inc (NASDAQ: BCAB) Trading Performance Indicators
Check out the current performance indicators for BioAtla Inc (BCAB). In the past quarter, the stock posted a quick ratio of 3.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of BioAtla Inc (BCAB)
Analysing the last 5-days average volume posted by the [BioAtla Inc, BCAB], we can find that recorded value of 1.61 million was better than the volume posted last year of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 5.08%. Additionally, its Average True Range was 0.22.
During the past 100 days, BioAtla Inc’s (BCAB) raw stochastic average was set at 26.71%, which indicates a significant increase from 4.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.02% in the past 14 days, which was higher than the 102.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9083, while its 200-day Moving Average is $2.1370. Now, the first resistance to watch is $1.6133. This is followed by the second major resistance level at $1.7167. The third major resistance level sits at $1.7933. If the price goes on to break the first support level at $1.4333, it is likely to go to the next support level at $1.3567. Should the price break the second support level, the third support level stands at $1.2533.
BioAtla Inc (NASDAQ: BCAB) Key Stats
There are currently 48,346K shares outstanding in the company with a market cap of 66.60 million. Presently, the company’s annual sales total 0 K according to its annual income of -123,460 K. Last quarter, the company’s sales amounted to 11,000 K and its income totaled -10,590 K.
